

ONCOLOGY CLINICAL RESEARCH - OPEN BREAST PROTOCOLS AS OF 11/09/2011

Disease Site	Study #	STUDY TITLE
BREAST	CALGB 40503	A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy plus Bevacizumab for Women with Hormone Receptor-Positive Advanced Breast Cancer – will close to accrual November 30, 2011.
	NSABP B-43	A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and radiation Therapy Alone for Women with HER-2 Positive Ductal Carcinoma in Situ Resected by Lumpectomy
	NCCTG 0733	A Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and Anthracycline and/or a Taxane
	NSABP B-47	A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer